Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Alzheimer's Disease

  Free Subscription


Articles published in Nat Med

Retrieve available abstracts of 22 articles:
HTML format



Single Articles


    February 2022
  1. O'LEARY K
    Mapping the mediators of Alzheimer's disease.
    Nat Med. 2022 Feb 28. pii: 10.1038/d41591-022-00037.
    PubMed    


    September 2021
  2. PASCOAL TA, Benedet AL, Ashton NJ, Kang MS, et al
    Microglial activation and tau propagate jointly across Braak stages.
    Nat Med. 2021;27:1592-1599.
    PubMed     Abstract available


  3. PERLMUTTER JS
    Aducanumab: look before leaping.
    Nat Med. 2021;27:1499.
    PubMed    


  4. CUMMINGS J
    Why aducanumab is important.
    Nat Med. 2021;27:1498.
    PubMed    


    August 2021
  5. JABBARI E, Duff KE
    Tau-targeting antibody therapies: too late, wrong epitope or wrong target?
    Nat Med. 2021;27:1341-1342.
    PubMed    


    July 2021
  6. RABINOVICI GD
    Dominantly inherited Alzheimer's disease: a compass for drug development.
    Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01434.
    PubMed    


    June 2021
  7. SALLOWAY S, Farlow M, McDade E, Clifford DB, et al
    A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Nat Med. 2021 Jun 21. pii: 10.1038/s41591-021-01369.
    PubMed     Abstract available


  8. HANSSON O
    Biomarkers for neurodegenerative diseases.
    Nat Med. 2021;27:954-963.
    PubMed     Abstract available


    May 2021
  9. PALMQVIST S, Tideman P, Cullen N, Zetterberg H, et al
    Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
    Nat Med. 2021 May 24. pii: 10.1038/s41591-021-01348.
    PubMed     Abstract available


    April 2021
  10. VOGEL JW, Young AL, Oxtoby NP, Smith R, et al
    Four distinct trajectories of tau deposition identified in Alzheimer's disease.
    Nat Med. 2021 Apr 29. pii: 10.1038/s41591-021-01309.
    PubMed     Abstract available


    January 2021
  11. DUJARDIN S, Commins C, Lathuiliere A, Beerepoot P, et al
    Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
    Nat Med. 2021 Jan 29. pii: 10.1038/s41591-021-01251.
    PubMed    


    November 2020
  12. ARNOLD C
    Post-hoc analysis could give new life to the Alzheimer's drug aducanumab.
    Nat Med. 2020 Nov 2. pii: 10.1038/d41591-020-00031.
    PubMed    


    June 2020
  13. DUJARDIN S, Commins C, Lathuiliere A, Beerepoot P, et al
    Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
    Nat Med. 2020 Jun 22. pii: 10.1038/s41591-020-0938.
    PubMed     Abstract available


    May 2020
  14. ZHOU Y, Song WM, Andhey PS, Swain A, et al
    Author Correction: Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.
    Nat Med. 2020 May 14. pii: 10.1038/s41591-020-0922.
    PubMed     Abstract available


    April 2020
  15. JOHNSON ECB, Dammer EB, Duong DM, Ping L, et al
    Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation.
    Nat Med. 2020 Apr 13. pii: 10.1038/s41591-020-0815.
    PubMed     Abstract available


    March 2020
  16. BATEMAN RJ, Barthelemy NR, Horie K
    Another step forward in blood-based diagnostics for Alzheimer's disease.
    Nat Med. 2020 Mar 4. pii: 10.1038/s41591-020-0797.
    PubMed    


  17. THIJSSEN EH, La Joie R, Wolf A, Strom A, et al
    Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.
    Nat Med. 2020 Mar 2. pii: 10.1038/s41591-020-0762.
    PubMed     Abstract available


  18. JANELIDZE S, Mattsson N, Palmqvist S, Smith R, et al
    Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.
    Nat Med. 2020 Mar 2. pii: 10.1038/s41591-020-0755.
    PubMed     Abstract available


  19. BARTHELEMY NR, Li Y, Joseph-Mathurin N, Gordon BA, et al
    A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease.
    Nat Med. 2020;26:398-407.
    PubMed     Abstract available


    January 2020
  20. ZHOU Y, Song WM, Andhey PS, Swain A, et al
    Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.
    Nat Med. 2020;26:131-142.
    PubMed     Abstract available


    November 2019
  21. ARBOLEDA-VELASQUEZ JF, Lopera F, O'Hare M, Delgado-Tirado S, et al
    Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report.
    Nat Med. 2019 Nov 4. pii: 10.1038/s41591-019-0611.
    PubMed     Abstract available


  22. ZALOCUSKY KA, Nelson MR, Huang Y
    An Alzheimer's-disease-protective APOE mutation.
    Nat Med. 2019 Nov 4. pii: 10.1038/s41591-019-0634.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: